Health Condition 1: D499- Neoplasm of unspecified behavior of unspecified site
Conditions
Interventions
Intervention1: Methotrexate Infusion: Injection of Methotrexate will be administered as per the standard treatment protocol for the type of cancer by the treating physician
Sponsors
Siddhartha Krishna Deka
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with various cancers undergoing MTX chemotherapy, receiving Methotrexate at a dose of more than 500 mg 2. Age: Above 18 years and less than 65 years 3. Gender: Male and Female 4. Those who are willing to give written informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnancy and lactation. 2. History of a drug reaction or allergy to Methotrexate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Proportion of patients with C677T and A1298C MTHFR Genetic polymorphism in cases of Methotrexate toxicity as well as in controls (Grade 0). 2.Correlation of C677T and A1298C MTHFR Genetic Polymorphism with Serum Levels of Methotrexate. Timepoint: 24, 48, and 72 hours | — |
Secondary
| Measure | Time frame |
|---|---|
| The correlation between genetic polymorphism and hematologic and non-hematologic toxicities.Timepoint: 24, 48, and 72 hours | — |
Countries
India
Contacts
Public ContactDr C Prabhakar Reddy
Department of Clinical Pharmacology and Therapeutics, Nizams Institute of Medical Sciences
Outcome results
None listed